Browsing Tag
PharmaLogic Holdings Corp.
2 posts
![Ratio Therapeutics’ $70 million Series C financing will support the ATLAS trial of [Ac-225]RTX-2358, expand its targeted radiotherapeutics pipeline and strengthen radiopharmaceutical manufacturing capacity. Representative image.](https://business-news-today.com/wp-content/uploads/2026/07/Ratio-Therapeutics-raises-70-million-to-advance-ATLAS-trial-and-radiopharmaceutical-manufacturing-380x280.png)
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
PharmaLogic announces strategic expansion with Agilera deal amid rising demand for nuclear medicine
PharmaLogic moves to acquire Agilera, boosting global radiopharmaceutical CDMO leadership. Find out how this deal reshapes therapeutic manufacturing worldwide.